News | September 24, 2013

Two-Item Questionnaire Aids Depression Screening for Radiation Therapy Patients

ASTRO Clinical Study Questionnaire Depression Screening Radiation Therapy

September 24, 2013 — Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.

The Radiation Oncology Therapy Group (RTOG) Community Clinical Oncology Program (CCOP)-supported multi-institutional clinical study screened 455 patients receiving radiation treatment at 37 centers around the United States. Participants in the study were seeking treatment for breast cancer (45 percent); GI cancer (11 percent); lung cancer (10 percent); gynecologic cancer (6 percent); or other cancers (27 percent). Sixty-six percent of the patients in the trial (298) were women.

Depression screenings were performed before or within two weeks of treatment of the initial cancer diagnosis. The screening forms included the single-item National Comprehensive Cancer Network-Distress Thermometer (NCCN-DT); the Hopkins Symptom Checklist (HSCL-25); and the nine-item Patient Health Questionnaire, (PHQ-9), which includes Patient Health Questionnaire-2 (PHQ-2) as its first two questions. All of the study participants answered the screening questionnaires with 100 percent completion.

Patients received the PHQ-9 and were asked if, within the past two weeks, they had “little interest or pleasure in doing things,” or “if they were feeling down, depressed or hopeless.” It was discovered that patients’ responses to these two questions (the PHQ-2) were as useful in identifying depression as results from the entire PHQ-9, and were more indicative than results from the NCCN-DT.

Within the study, a total of 75 patients (16 percent) screened positively for depressive symptoms. PHQ-9 and PHQ-2 had similar accuracy in detecting depression with an area under the curve (AUC) of approximately 0.83 for each and was superior to the HLSC-25 (.79) and the NCCN-DT (.60).

Of the facilities included in the study, 68 percent offer mental health services. Patients who screened positive for depression symptoms, along with a systematic sample of patients who screened negative, were administered the Structured Clinical Interview for DSM-IV (SCID) Mood Disorder modules by telephone. The study determined that screening in an RT setting was well received by patients and feasible.

“Detection of depression in cancer patients is an important public health priority, and the ability to screen and treat cancer patients for depression can have a major impact on a patient’s quality of life,” said William Small Jr., M.D., FASTRO, presenting author of the study and chairman of the Department of Radiation Oncology at Loyola University Chicago. “This study was designed to test the feasibility of screening for major depression in cancer patients receiving radiation therapy.

The ability of a two-question survey to effectively screen for depression will hopefully prompt more centers to screen and to refer patients in need of mental health services,” said Lynn I. Wagner, Ph.D., principal investigator of the study and an associate professor in the Department of Psychiatry and Behavioral Sciences at the Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago.

The abstract, “RTOG 0841: Two Item Questionnaire Effectively Screens for Depression in Cancer Patients Receiving Radiotherapy,” was presented at ASTRO’s Annual Meeting in the Plenary session Sept. 23.

For more information: www.astro.org

Related Content

ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Varian Halcyon Commissioned at MedStar Southern Maryland Hospital Center With IBA's myQA Halo
News | Quality Assurance (QA) | April 04, 2019
IBA (Ion Beam Applications S.A.) announced the successful commissioning of the Varian Halcyon at the Radiation Oncology...
Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill. Interview with Mark Pankuch, Ph.D.

Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill.
 

Feature | April 02, 2019 | Dave Fornell, Editor and A.J. Connell
April 2, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine w
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...